Please try another search
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease dementia and Dementia with Lewy bodies. The company’s product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Name | Age | Since | Title |
---|---|---|---|
Kelly A. Romano | 60 | 2020 | Independent Chairwoman of the Board |
Mark J. Litton | 54 | 2019 | President, CEO & Director |
John M. Fluke | 79 | 2014 | Independent Director |
Joseph Eric Edelman | 66 | 2020 | Independent Director |
Marwan Noel Sabbagh | 56 | 2022 | Member of Scientific Advisory Board |
Grant E. Pickering | 54 | 2022 | Independent Director |
James A. Johnson | 65 | 2020 | Independent Director |
Barbara A. Kosacz | 64 | 2021 | Independent Director |
Anton P. Porsteinsson | - | 2022 | Member of Scientific Advisory Board |
Michael A. Panzara | 56 | 2022 | Independent Director |
John Olichney | - | 2022 | Member of Scientific Advisory Board |
Lon S. Schneider | - | 2022 | Member of Scientific Advisory Board |
Paul Winner | - | 2022 | Member of Scientific Advisory Board |
Pierre N. Tariot | - | 2022 | Member of Scientific Advisory Board |
Hans Moebius | 67 | 2019 | Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review